Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

To main content To sitemap To news Check availability details

New and improved biological drugs in healthcare

When new biological drugs are developed, it is important that healthcare becomes involved earlier in the value chain. It is also important that new biological drugs that are developed become available for healthcare and, in the long run, for patients. This call welcomes innovative projects where researchers, companies and healthcare collaborate to develop, improve and / or make biological drugs available.

The offer in brief

What can you apply for?

We welcome applications from innovative collaborative projects that will develop or improve biological drugs and / or make biological drugs easier to use / easily accessible in healthcare and for patients.

Who can apply?

The proposal must include at least two project partners, a health care organization and a company. Universities, colleges, research institutes or patient associations can also participate with advantage, but there are no eligibility requirements.

How much can you apply for?

A project can apply for a maximum of SEK 5 million over two to three years.

Important dates

Are you interested in this the offer? Book an information meeting on Monday 6 September at 10 am. At the meeting, the call team will tell you more about the call and answer questions. The meeting will be held in Teams. A link to the meeting will be published on this page well in advance of the meeting.

    • The call in detail

    • With this offer, we want to develop and improve biological drugs in collaboration with the health care system to further strengthen Sweden's position in biological drugs.

      The next generation of biological drugs involves complex challenges where healthcare needs to be involved early in the value chain. It is also important that new biological drugs become available to healthcare and patients. This call welcomes innovative project where researchers, companies and healthcare collaborate to develop, improve and make available biological drugs.

      The proposal must include at least two project parties, an organization in health care and a company. Universities, colleges, research institutes and patient associations can also participate, but there are no eligibility requirements. One of these parties must be the main applicant ( coordinator). The parties must have prepared the project proposal jointly.

      A project can apply for a maximum of five million kronor over two to three years.

      With this offer, we want to develop and improve biological drugs in collaboration with the health care system to further strengthen Sweden's position in biological drugs.

      The next generation of biological drugs involves complex challenges where healthcare needs to be involved early in the value chain. It is also important that new biological drugs become available to healthcare and patients. This call welcomes innovative project where researchers, companies and healthcare collaborate to develop, improve and make available biological drugs.

      The proposal must include at least two project parties, an organization in health care and a company. Universities, colleges, research institutes and patient associations can also participate, but there are no eligibility requirements. One of these parties must be the main applicant ( coordinator). The parties must have prepared the project proposal jointly.

      A project can apply for a maximum of five million kronor over two to three years.

    • The call aims to give Sweden a leading role in the field of biological drugs by strengthening collaboration between healthcare, business and research. Collaboration increases the opportunities for health care to receive new biological drugs, increases the connection between research and treatment, as well as the development of new diagnostics and individualized treatment strategies. In this call for proposals, we place special focus on new individualized treatments for very seriously ill people.

      We are looking for project in different steps in the value chain, for example:

      • in the early phase where new or existing biological drugs are developed to improve use, reduce side effects and thereby increase patient benefit.
      • the aim of developing processes to streamline production and increase availability.
      • in the later phase to improve formulations or distribution systems that make it easier for healthcare and the patient.


      The next generation of biological drugs entails a complex challenge where both industrial and clinical competence is needed already in the definition phase of the research challenge. The projects will contribute to better and more effective biological drugs and increase the availability of health care. The financial contribution from Vinnova to the health and medical care party will make it possible to free up resources so that active collaboration can take place.

      The project must be of a general nature. The innovation must be in general methods, techniques or platforms, and the results must be transferable to other project that can benefit from the new knowledge.

      A biological medicinal product here refers to a preparation whose active substance has been produced in or purified from material of biological origin. Vinnova has the task of promoting sustainable growth by improving the conditions for innovation. Improved conditions for innovation strengthen the capacity to achieve the goals for sustainable development in Agenda 2030. Through our efforts, we contribute to the global commitment to achieve the goals.

      Collaboration, concentration and innovation will be crucial to achieve the goals in Agenda 2030. With this call for proposals, we want more people to collaboratively develop their innovative capacity and create new solutions that contribute to the goals, within the framework of the call's priorities.

      Gender equality is a prerequisite for sustainable growth and is found in Agenda 2030, as an objective in itself but also as a perspective that should permeate the work with all objective. The call must therefore contribute to a gender-equal development of society linked to two main perspectives.

      One aspect that Vinnova follows up and assesses is whether both women and men receive the grant on an equal basis, participate in and have influence over the project (see section Assessment of received applications and the actor criterion).

      Another important aspect is about analyzing and deciding whether there are gender and / or gender aspects that are relevant within the solution's problem area and utilization. This question is mandatory for all applicant and can be found under the heading " Project tasks".

      In this call for proposals, the question is the basis for assessment under the potential criterion (see section Assessment of received applications).

      Results from research and innovation that are made freely available provide an increased opportunity for more people to contribute to solutions to societal challenges. The call will contribute to more results being made freely available to everyone and scientific publication will take place with open access.

      Vinnova has the task of promoting sustainable growth by improving the conditions for innovation. Improved conditions for innovation strengthen the capacity to achieve the goals for sustainable development in Agenda 2030. Through our efforts, we contribute to the global commitment to achieve the goals.

      Our work to contribute to the goals in Agenda 2030

      Collaboration, concentration and innovation will be crucial to achieve the goals in Agenda 2030. With this call for proposals, we want more people to collaboratively develop their innovative capacity and create new solutions that contribute to the goals, within the framework of the call's priorities.

      Gender equality is a prerequisite for sustainable growth and is found in Agenda 2030 as an objective in itself, but also as a perspective that should permeate the work with all objective. The call must therefore contribute to a gender-equal development of society linked to two main perspectives:

      • One perspective is that both women and men take part in the grant and participate in and have influence over the project in an equal way.
      • The second perspective is about the project analyzing and deciding whether there are gender equality aspects (gender or gender) that are relevant within the solution's problem area and utilization.

      Equal innovation for those seeking funding

      The call aims to give Sweden a leading role in the field of biological drugs by strengthening collaboration between healthcare, business and research. Collaboration increases the opportunities for health care to receive new biological drugs, increases the connection between research and treatment, as well as the development of new diagnostics and individualized treatment strategies. In this call for proposals, we place special focus on new individualized treatments for very seriously ill people.

      We are looking for project in different steps in the value chain, for example:

      • in the early phase where new or existing biological drugs are developed to improve use, reduce side effects and thereby increase patient benefit.
      • the aim of developing processes to streamline production and increase availability.
      • in the later phase to improve formulations or distribution systems that make it easier for healthcare and the patient.


      The next generation of biological drugs entails a complex challenge where both industrial and clinical competence is needed already in the definition phase of the research challenge. The projects will contribute to better and more effective biological drugs and increase the availability of health care. The financial contribution from Vinnova to the health and medical care party will make it possible to free up resources so that active collaboration can take place.

      The project must be of a general nature. The innovation must be in general methods, techniques or platforms, and the results must be transferable to other project that can benefit from the new knowledge.

      A biological medicinal product here refers to a preparation whose active substance has been produced in or purified from material of biological origin. Vinnova has the task of promoting sustainable growth by improving the conditions for innovation. Improved conditions for innovation strengthen the capacity to achieve the goals for sustainable development in Agenda 2030. Through our efforts, we contribute to the global commitment to achieve the goals.

      Collaboration, concentration and innovation will be crucial to achieve the goals in Agenda 2030. With this call for proposals, we want more people to collaboratively develop their innovative capacity and create new solutions that contribute to the goals, within the framework of the call's priorities.

      Gender equality is a prerequisite for sustainable growth and is found in Agenda 2030, as an objective in itself but also as a perspective that should permeate the work with all objective. The call must therefore contribute to a gender-equal development of society linked to two main perspectives.

      One aspect that Vinnova follows up and assesses is whether both women and men receive the grant on an equal basis, participate in and have influence over the project (see section Assessment of received applications and the actor criterion).

      Another important aspect is about analyzing and deciding whether there are gender and / or gender aspects that are relevant within the solution's problem area and utilization. This question is mandatory for all applicant and can be found under the heading " Project tasks".

      In this call for proposals, the question is the basis for assessment under the potential criterion (see section Assessment of received applications).

      Results from research and innovation that are made freely available provide an increased opportunity for more people to contribute to solutions to societal challenges. The call will contribute to more results being made freely available to everyone and scientific publication will take place with open access.

      Vinnova has the task of promoting sustainable growth by improving the conditions for innovation. Improved conditions for innovation strengthen the capacity to achieve the goals for sustainable development in Agenda 2030. Through our efforts, we contribute to the global commitment to achieve the goals.

      Our work to contribute to the goals in Agenda 2030

      Collaboration, concentration and innovation will be crucial to achieve the goals in Agenda 2030. With this call for proposals, we want more people to collaboratively develop their innovative capacity and create new solutions that contribute to the goals, within the framework of the call's priorities.

      Gender equality is a prerequisite for sustainable growth and is found in Agenda 2030 as an objective in itself, but also as a perspective that should permeate the work with all objective. The call must therefore contribute to a gender-equal development of society linked to two main perspectives:

      • One perspective is that both women and men take part in the grant and participate in and have influence over the project in an equal way.
      • The second perspective is about the project analyzing and deciding whether there are gender equality aspects (gender or gender) that are relevant within the solution's problem area and utilization.

      Equal innovation for those seeking funding

    • Project must consist of at least one health care organization and at least one company. Universities, colleges, research institutes and patient associations can also be involved, but there are no eligibility requirements. One of these parties must be the main applicant ( coordinator). The parties must have prepared the project proposal jointly.

      A company that is a beneficiary must be registered as a limited company in Sweden with active activities in research and development as well as business operations.

      International parties are welcome to participate in the proposed project, but can not be the project coordinator. Organizations registered outside Sweden must have a branch or place of business in Sweden in order to receive funding.

      If necessary, appropriate research and innovation infrastructures can be used, to add expertise and networks, but these cannot be thecoordinator

      Project must consist of at least one health care organization and at least one company. Universities, colleges, research institutes and patient associations can also be involved, but there are no eligibility requirements. One of these parties must be the main applicant ( coordinator). The parties must have prepared the project proposal jointly.

      A company that is a beneficiary must be registered as a limited company in Sweden with active activities in research and development as well as business operations.

      International parties are welcome to participate in the proposed project, but can not be the project coordinator. Organizations registered outside Sweden must have a branch or place of business in Sweden in order to receive funding.

      If necessary, appropriate research and innovation infrastructures can be used, to add expertise and networks, but these cannot be thecoordinator

    • Activities for funding can be applied for

      This call for proposals finances activities within collaborative projects of the type “Industrial research” or “Experimental development”, as defined in Vinnova's support ordinance.

      Eligible costs

      Our funding is through funding. Funding for organizations that conduct financial activities covered by rules on state support.

      The rules govern, among other things, the types of costs and the proportion of them that may be covered by funding.

      Government support for financial activities (companies)

      Rules for which costs are eligible

      The following costs are eligible:

      • Personnel costs
      • Costs for equipment, land and buildings to the extent and during the time they are used for the project
      • Costs for consultants and licenses etc.
      • Other direct costs
      • Indirect costs

      More information about the term, limitation and scope for each type of cost mentioned above can be read in Instructions for Vinnova's term on eligible costs.

      Support bases

      Commission Regulation (EU) No 651/2014 (GBER)

      Funding for organizations that conduct financial activities covered by state support rules. Read more about government support on our website.

      By economic activities we mean all activities that involve offering goods and services in a market. This is independent of the legal position, how the business is financed and whether the unit has been established for profit or not. Decisive is the type of activities that are conducted, not company form.

      The rules govern, among other things, the types of costs and the proportion ( aid intensity) of an organization's eligible costs that may be covered by funding. The level of support depends on the size of the organization and the nature of the project activities carried out.

      Funding granted in accordance with Vinnova's ordinance (2015: 208) on state support for research and development and innovation and Article 25 of Commission Regulation (EU) No 651/2014 (GBER).

      The following support bases can be used for the organizations that conduct financial activities:

      Industrial research: “planned research or critical analysis, which aims to acquire new knowledge and new skills to develop new products, processes or services, or to significantly improve existing products, processes or services. This involves the creation of components that form part of complex systems, and may include the construction of prototypes in a laboratory environment or in an environment with simulated interfaces to existing systems and to pilot activities, if this is necessary for industrial research, in particular for general technology validation ".

      Experimental development: “to acquire, combine, shape and use existing scientific, technical, business and other relevant knowledge and skills for the purpose of developing new or improved products, processes or services. This may also include e.g. activities aimed at conceptual definition, planning and documentation of new products, processes or services. Experimental development may include the design of prototypes, demonstration, pilot work, testing and validation of new or improved products, processes or services in environments that correspond to realistic operating conditions, where the primary purpose is to make further technical improvements to the products, processes or services still are not fixed, This may involve the development of a commercially useful prototype or pilot project which is necessarily the final commercial product and which is too expensive to produce to be used only for demonstration and evaluation. Experimental development does not involve routine or recurring changes to existing goods, manufacturing methods, manufacturing processes, services or other ongoing activities, although such changes may involve improvements. "

      Minor Support (de minimis support)

      Small companies can apply for funding with section 2 of the ordinance (2015: 208) on state support for research and development as well as innovation and commission ordinance no. 1407/2013 on support of minor importance (de minimis support). Before such support can be granted, a certificate support must be submitted to Vinnova. This is done in connection with proposal. The maximum allowable support of minor importance is 200,000 euros per recipient during the last three tax years. More information is available on our website Government support for financial activities (companies) under the heading Support of minor importance.

      Funding which does not constitute State aid

      Organizations carrying out non-economic activities may be granted funding when participating in their non-financial activities.

      Activities for funding can be applied for

      This call for proposals finances activities within collaborative projects of the type “Industrial research” or “Experimental development”, as defined in Vinnova's support ordinance.

      Eligible costs

      Our funding is through funding. Funding for organizations that conduct financial activities covered by rules on state support.

      The rules govern, among other things, the types of costs and the proportion of them that may be covered by funding.

      Government support for financial activities (companies)

      Rules for which costs are eligible

      The following costs are eligible:

      • Personnel costs
      • Costs for equipment, land and buildings to the extent and during the time they are used for the project
      • Costs for consultants and licenses etc.
      • Other direct costs
      • Indirect costs

      More information about the term, limitation and scope for each type of cost mentioned above can be read in Instructions for Vinnova's term on eligible costs.

      Support bases

      Commission Regulation (EU) No 651/2014 (GBER)

      Funding for organizations that conduct financial activities covered by state support rules. Read more about government support on our website.

      By economic activities we mean all activities that involve offering goods and services in a market. This is independent of the legal position, how the business is financed and whether the unit has been established for profit or not. Decisive is the type of activities that are conducted, not company form.

      The rules govern, among other things, the types of costs and the proportion ( aid intensity) of an organization's eligible costs that may be covered by funding. The level of support depends on the size of the organization and the nature of the project activities carried out.

      Funding granted in accordance with Vinnova's ordinance (2015: 208) on state support for research and development and innovation and Article 25 of Commission Regulation (EU) No 651/2014 (GBER).

      The following support bases can be used for the organizations that conduct financial activities:

      Industrial research: “planned research or critical analysis, which aims to acquire new knowledge and new skills to develop new products, processes or services, or to significantly improve existing products, processes or services. This involves the creation of components that form part of complex systems, and may include the construction of prototypes in a laboratory environment or in an environment with simulated interfaces to existing systems and to pilot activities, if this is necessary for industrial research, in particular for general technology validation ".

      Experimental development: “to acquire, combine, shape and use existing scientific, technical, business and other relevant knowledge and skills for the purpose of developing new or improved products, processes or services. This may also include e.g. activities aimed at conceptual definition, planning and documentation of new products, processes or services. Experimental development may include the design of prototypes, demonstration, pilot work, testing and validation of new or improved products, processes or services in environments that correspond to realistic operating conditions, where the primary purpose is to make further technical improvements to the products, processes or services still are not fixed, This may involve the development of a commercially useful prototype or pilot project which is necessarily the final commercial product and which is too expensive to produce to be used only for demonstration and evaluation. Experimental development does not involve routine or recurring changes to existing goods, manufacturing methods, manufacturing processes, services or other ongoing activities, although such changes may involve improvements. "

      Minor Support (de minimis support)

      Small companies can apply for funding with section 2 of the ordinance (2015: 208) on state support for research and development as well as innovation and commission ordinance no. 1407/2013 on support of minor importance (de minimis support). Before such support can be granted, a certificate support must be submitted to Vinnova. This is done in connection with proposal. The maximum allowable support of minor importance is 200,000 euros per recipient during the last three tax years. More information is available on our website Government support for financial activities (companies) under the heading Support of minor importance.

      Funding which does not constitute State aid

      Organizations carrying out non-economic activities may be granted funding when participating in their non-financial activities.

    • In this call, each project apply for a maximum of SEK 5 million.

      The project period can be between 2 and 3 years.

      The call's preliminary budget is a maximum of SEK 50 million.

      In this call, each project apply for a maximum of SEK 5 million.

      The project period can be between 2 and 3 years.

      The call's preliminary budget is a maximum of SEK 50 million.

    • We will only assess applications that meet the following formal eligibility requirements:

      • Project must consist of at least one health and medical care organization and at least one company with research and development in Sweden
      • The coordinator is a Swedish organization and consists of a party from the health service, a company or a research organization.
      • The project parties are legal entities.
      • Companies applying for funding must be registered as a limited company.
      • Proposal is in Swedish or English.
      • Proposal contains all mandatory appendices according to section (10) How to apply, written in the mandatory templates within the specified maximum number of pages.
      • Proposal does not contain any appendices other than the mandatory appendices provided by Vinnova.

      We will only assess applications that meet the following formal eligibility requirements:

      • Project must consist of at least one health and medical care organization and at least one company with research and development in Sweden
      • The coordinator is a Swedish organization and consists of a party from the health service, a company or a research organization.
      • The project parties are legal entities.
      • Companies applying for funding must be registered as a limited company.
      • Proposal is in Swedish or English.
      • Proposal contains all mandatory appendices according to section (10) How to apply, written in the mandatory templates within the specified maximum number of pages.
      • Proposal does not contain any appendices other than the mandatory appendices provided by Vinnova.

    • What do we assess?

      Applications that meet the formal requirements will be assessed on the following three criteria, each of which consists of a number of sub-criteria:

      Potential

      • Relevance of the project in relation to the aim call and the impact goals program (see appendix)
      • The project's potential to contribute to improved healthcare and / or value for the patient
      • The project value's novelty value and degree of innovation
      • To what extent does the project increase collaboration between healthcare and industry
      • To what extent is the project idea focused on generic solutions and widely applicable knowledge
      • Scientific quality in issue and method and potential to contribute to new progress
      • The potential project results to contribute to increased gender equality

      Actors

      • Knowledge, competence and experience of the members of the project group; especially with the project manager and other key people
      • Access to relevant competence in the project group, regarding for example clinical competence, technology, business models and science
      • Players' ability to describe and relate to competitors and collaboration opportunities, both nationally and internationally
      • The project partners' involvement in the project, with working hours and other resources
      • Existence of new collaboration, between project partners who have not previously collaborated
      • Engagement of end users and others who can benefit from project results
      • How well the team (key people) is composed in terms of gender distribution, as well as the distribution of power and influence between women and men

      Feasibility

      • A project plan that clearly describes how specified activities are to be carried out
      • Plans and activities that demonstrate the commitment, participation and mutual communication of all parties
      • The project activities, schedule and milestones are realistic and relevant in relation to what is required to achieve expected results
      • Reasonable budget as well as credibility in funding and access to other resources for implementation
      • Relevance and credibility of the risk analysis
      • A credible plan for the implementation and use of project results
      • Ethical considerations, where applicable
      • How well gender equality aspects are integrated into the project plan

      What do we assess?

      Applications that meet the formal requirements will be assessed on the following three criteria, each of which consists of a number of sub-criteria:

      Potential

      • Relevance of the project in relation to the aim call and the impact goals program (see appendix)
      • The project's potential to contribute to improved healthcare and / or value for the patient
      • The project value's novelty value and degree of innovation
      • To what extent does the project increase collaboration between healthcare and industry
      • To what extent is the project idea focused on generic solutions and widely applicable knowledge
      • Scientific quality in issue and method and potential to contribute to new progress
      • The potential project results to contribute to increased gender equality

      Actors

      • Knowledge, competence and experience of the members of the project group; especially with the project manager and other key people
      • Access to relevant competence in the project group, regarding for example clinical competence, technology, business models and science
      • Players' ability to describe and relate to competitors and collaboration opportunities, both nationally and internationally
      • The project partners' involvement in the project, with working hours and other resources
      • Existence of new collaboration, between project partners who have not previously collaborated
      • Engagement of end users and others who can benefit from project results
      • How well the team (key people) is composed in terms of gender distribution, as well as the distribution of power and influence between women and men

      Feasibility

      • A project plan that clearly describes how specified activities are to be carried out
      • Plans and activities that demonstrate the commitment, participation and mutual communication of all parties
      • The project activities, schedule and milestones are realistic and relevant in relation to what is required to achieve expected results
      • Reasonable budget as well as credibility in funding and access to other resources for implementation
      • Relevance and credibility of the risk analysis
      • A credible plan for the implementation and use of project results
      • Ethical considerations, where applicable
      • How well gender equality aspects are integrated into the project plan

    • The assessment takes place in competition between received applications.

      Applications that meet the formal requirements will be assessed by international experts.

      The highest-ranked project proposals are called for an interview, in which at least one representative from each participant and other key actors are expected to participate. The interviews aim to clarify any ambiguities in the applications and clarify the collaboration between the participants in the project.

      The results from the interviews, together with previous assessments, form the basis for recommendations for decisions.

      Vinnova reserves the right to have a portfolio perspective when selecting applications that are recommended for decision.

      The formal decisions are made and communicated to the applicant by Vinnova.

      The assessment takes place in competition between received applications.

      Applications that meet the formal requirements will be assessed by international experts.

      The highest-ranked project proposals are called for an interview, in which at least one representative from each participant and other key actors are expected to participate. The interviews aim to clarify any ambiguities in the applications and clarify the collaboration between the participants in the project.

      The results from the interviews, together with previous assessments, form the basis for recommendations for decisions.

      Vinnova reserves the right to have a portfolio perspective when selecting applications that are recommended for decision.

      The formal decisions are made and communicated to the applicant by Vinnova.

    • About our decisions

      How much each party in the project is granted in funding stated in the decision. Funding will be granted with the support of Vinnova's ordinance SFS 2015: 208]. The basis for support is stated in the decision and also governs which costs are eligible.

      Our decision to grant or reject a proposal is not subject to appeal.

      Term for granted funding

      For granted funding, our general terms and conditions for fundingapply. The terms and conditions include rules on project agreements, conditions for payment, follow-up, reporting and utilization of results.

      Our rules and term for funding

      special conditionsalso apply to everyone who is granted funding

      The project must be represented by at least one Participant in the program conferences, seminars and network meetings organized within the Biological Medicines program. The cost of such participation is eligible.

      Additional special conditions can be determined for individual project.

      If you do not follow our term, you may be liable for a refund. This also applies if you have been granted funding incorrectly or with funding

      About our decisions

      How much each party in the project is granted in funding stated in the decision. Funding will be granted with the support of Vinnova's ordinance SFS 2015: 208]. The basis for support is stated in the decision and also governs which costs are eligible.

      Our decision to grant or reject a proposal is not subject to appeal.

      Term for granted funding

      For granted funding, our general terms and conditions for fundingapply. The terms and conditions include rules on project agreements, conditions for payment, follow-up, reporting and utilization of results.

      Our rules and term for funding

      special conditionsalso apply to everyone who is granted funding

      The project must be represented by at least one Participant in the program conferences, seminars and network meetings organized within the Biological Medicines program. The cost of such participation is eligible.

      Additional special conditions can be determined for individual project.

      If you do not follow our term, you may be liable for a refund. This also applies if you have been granted funding incorrectly or with funding

    • To apply for funding, fill in a web-based form on Vinnovas Intressentportal, which can be accessed via www.vinnova.se. There you also upload the following attachments:

      Project description

      The project description may amount to a maximum of 10 single-column A4 pages in portrait format, with 12 points of black text. References to web pages and similar information will not be considered.

      CV Annex
      The CV appendix must include the CV of the project manager, a representative of each participant and other key people in the project. Varje CV may include a maximum of 1 A4 page, written in 12-point black text.

      All project partners must be included in the CV appendix, including project partners who are not applying for funding.

      Budget

      The project budget must be reported in Vinnova's eservices portal. In addition, a separate budget appendix must be filled in. The budget of all project partners must be reported, including the budget for project partners who do not apply for funding.

      Certificate support must be signed and attached to the proposal for the actors seeking such. See more information under section (6) What we finance. It is mandatory to use the template that Vinnova provides on the call's website. It is not allowed to change the font, font size or formatting.

      The scope of the annexes may not exceed what is stated above and no further annexes may be attached.

      Templates for attachments can be found further down on the announcement page.

      To apply for funding, fill in a web-based form on Vinnovas Intressentportal, which can be accessed via www.vinnova.se. There you also upload the following attachments:

      Project description

      The project description may amount to a maximum of 10 single-column A4 pages in portrait format, with 12 points of black text. References to web pages and similar information will not be considered.

      CV Annex
      The CV appendix must include the CV of the project manager, a representative of each participant and other key people in the project. Varje CV may include a maximum of 1 A4 page, written in 12-point black text.

      All project partners must be included in the CV appendix, including project partners who are not applying for funding.

      Budget

      The project budget must be reported in Vinnova's eservices portal. In addition, a separate budget appendix must be filled in. The budget of all project partners must be reported, including the budget for project partners who do not apply for funding.

      Certificate support must be signed and attached to the proposal for the actors seeking such. See more information under section (6) What we finance. It is mandatory to use the template that Vinnova provides on the call's website. It is not allowed to change the font, font size or formatting.

      The scope of the annexes may not exceed what is stated above and no further annexes may be attached.

      Templates for attachments can be found further down on the announcement page.

    • Background

      The Swedish government has commissioned Vinnova and the Swedish Research Council to jointly design a national programme for protein research, method development and production of biological drugs.

      The research program is part of the government's strategic effort on life science (life science) which together will contribute to better health, to meet societal challenges, strengthen Sweden's position as a leading country in research and development and increase Sweden's competitiveness in an international perspective.

      The program will extend over a period of eight years (2016 - 2023) and has a budget of SEK 320 million. Private co-financing corresponding to an indicative 25 percent must be included in the program.

      Within the program, a project call - Development and production of biological drugs - with two application opportunities (2016 and 2017) and a center call - Center for Development and Production by Biologiska Läkemedel - with one application opportunity (2017) have so far been completed.

      The purpose of the program is to develop Sweden into a leading country in the development and production of biological drugs.

      The program's impact goals

      • to build a strong knowledge base around biological drugs
      • to strengthen healthcare opportunities to receive new biological drugs
      • to increase Sweden's attractiveness as a partner and for investments in research, development and innovation for the biological drugs of the future
      • to increase the competitiveness of companies in Sweden, in an international perspective
      • to increase collaboration between academia, industry and healthcare
      • to develop more efficient methods for the production of next-generation biological drugs

      Effect Logic

      The effect logic shows what we want to achieve with the investments made within the program. Results show what we want to see during each effort and shortly thereafter. Short-term effects show what should be achieved after about 5 years and long-term effects after about 10 years.

      Results

      • Publications in high quality journals
      • Improved collaboration between academia, industry and healthcare
      • Patent Applicationsr
      • New platforms for the production of biological drugs
      • Innovative technology for the development and production of biological drugs

      Short-term effects

      • Swedish research is internationally recognizedfor being excellent
      • New ways of workingimplemented, leading to more efficient transfer of results to healthcare
      • More efficient methods implementedfor development and production of next generation biological drugs
      • New systems for the production of biological drugs

      Long-term effects

      • Sweden is a leading countryin the development and production of biological drugs
      • Sweden receives new investments and collaborations in the field of biological drugs
      • Healthcare is well prepared for to take on new biological drugs
      • Swedish companies increase its competitiveness in the field of biological drugs

      Background

      The Swedish government has commissioned Vinnova and the Swedish Research Council to jointly design a national programme for protein research, method development and production of biological drugs.

      The research program is part of the government's strategic effort on life science (life science) which together will contribute to better health, to meet societal challenges, strengthen Sweden's position as a leading country in research and development and increase Sweden's competitiveness in an international perspective.

      The program will extend over a period of eight years (2016 - 2023) and has a budget of SEK 320 million. Private co-financing corresponding to an indicative 25 percent must be included in the program.

      Within the program, a project call - Development and production of biological drugs - with two application opportunities (2016 and 2017) and a center call - Center for Development and Production by Biologiska Läkemedel - with one application opportunity (2017) have so far been completed.

      The purpose of the program is to develop Sweden into a leading country in the development and production of biological drugs.

      The program's impact goals

      • to build a strong knowledge base around biological drugs
      • to strengthen healthcare opportunities to receive new biological drugs
      • to increase Sweden's attractiveness as a partner and for investments in research, development and innovation for the biological drugs of the future
      • to increase the competitiveness of companies in Sweden, in an international perspective
      • to increase collaboration between academia, industry and healthcare
      • to develop more efficient methods for the production of next-generation biological drugs

      Effect Logic

      The effect logic shows what we want to achieve with the investments made within the program. Results show what we want to see during each effort and shortly thereafter. Short-term effects show what should be achieved after about 5 years and long-term effects after about 10 years.

      Results

      • Publications in high quality journals
      • Improved collaboration between academia, industry and healthcare
      • Patent Applicationsr
      • New platforms for the production of biological drugs
      • Innovative technology for the development and production of biological drugs

      Short-term effects

      • Swedish research is internationally recognizedfor being excellent
      • New ways of workingimplemented, leading to more efficient transfer of results to healthcare
      • More efficient methods implementedfor development and production of next generation biological drugs
      • New systems for the production of biological drugs

      Long-term effects

      • Sweden is a leading countryin the development and production of biological drugs
      • Sweden receives new investments and collaborations in the field of biological drugs
      • Healthcare is well prepared for to take on new biological drugs
      • Swedish companies increase its competitiveness in the field of biological drugs
    • Date
      Change
      31 Aug 2021
      Date
      Change
      31 Aug 2021

    How to apply

    To apply for funding, you need to log in and complete an application form in our eServices portal. The application form contains questions about your project, the participants taking part in the project and your budget. 

    Download document templates for your attachments

    Plesae download the templates for the documents you need to attach to your application such as a CV or project description.

    Please allow enough time

    Please keep in mind that it takes time to complete an application. Filling in the templates can take several days, since they're based on analyses you need to do. Therefore, start the application well in advance. You can start filling in your details, then save and continue at a later time.

    When you've completed your application, please mark it as done ("klar"). You can unlock and make changes to your application at any time until the call closes. If you unlock your application, you must mark it as done ("klarmarkera") if you want the application registered when the call closes. 

    What happens after the call has closed?

    Once your application has been registered, we'll send a confirmation email to the person responsible for the user account, as well as to the project manager and the company signer. Please note that this may take a few hours after the call has closed.

    After the closing date, you can't register any new information. You may only add information to your application if we ask for it.

    Who can read your application?

    Applications submitted to us become official documents. However, we don't disclose information about business operations, inventions or research results if it can be assumed that someone will suffer economic damage if we do.

    This means that we must disclose the documents if someone requests them. However, we can black out information if we believe it could cause economic harm if disclosed.

    How we handle official documents and privacy

    Any questions?

    If you have any questions, please don't hesitate to contact us.

    Mats Jarekrans

    Utlysningsansvarig, Vinnova

    + 4684733185

    Jesper Orhammar

    Handläggare, Vinnova

    + 4684733153

    Therese Porsklint

    Administratör, Vinnova

    + 4684733028

    Abraham Mellkvist-Roos

    Vetenskapsrådet

    + 46765257613

    Teknisk support

    +46 8 473 32 99

    Fund­ed pro­jects

    Reference number 2021-03168

    Page statistics